No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGMO Sangamo Therapeutics
- 0.455
- +0.016+3.74%
Close Jul 12 16:00 ET
- 0.446
- -0.009-1.93%
Post 19:58 ET
94.38MMarket Cap-243P/E (TTM)
0.480High0.430Low3.78MVolume0.450Open0.438Pre Close1.71MTurnover2.21%Turnover RatioLossP/E (Static)207.51MShares1.67052wk High1.67P/B77.75MFloat Cap0.29152wk Low--Dividend TTM170.95MShs Float51.375Historical High--Div YieldTTM11.45%Amplitude0.291Historical Low0.451Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
The Market Doesn't Like What It Sees From Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues Yet As Shares Tumble 30%
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. (NASDAQ:SGMO) share price has dived 30% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous t
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
Comments
The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology.
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
1
$Sangamo Therapeutics(SGMO.US$ Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting
1
1
2
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
